[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Chen et al., 2023 - Google Patents

Evaluative effectiveness of follicular output rate, ovarian sensitivity index, and ovarian response prediction index for the ovarian reserve and response of low …

Chen et al., 2023

Document ID
665177036240162642
Author
Chen Z
Li W
Ma S
Li Y
Lv L
Huang K
Gong A
Publication year
Publication venue
Zygote

External Links

Snippet

The aim was to explore the implications of follicular output rate (FORT), ovarian sensitivity index (OSI), ovarian response prediction index (ORPI), and follicle-to-oocyte index (FOI) in low-prognosis patients defined by POSEIDON criteria. In total, 4030 fresh in vitro fertilization …
Continue reading at www.cambridge.org (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/368Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Sharma et al. Factors influencing the cumulative conception rate and discontinuation of in vitro fertilization treatment for infertility
Esinler et al. Impact of isolated obesity on ICSI outcome
Purcell et al. Asian ethnicity is associated with reduced pregnancy outcomes after assisted reproductive technology
Qiu et al. Effect of body mass index on pregnancy outcomes with the freeze-all strategy in women with polycystic ovarian syndrome
Hu et al. Perinatal outcome in young patients with diminished ovarian reserve undergoing assisted reproductive technology
McAvey et al. How many eggs are needed to produce an assisted reproductive technology baby: is more always better?
Aflatoonian et al. Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: a randomized, multi-center study
Xi et al. Comparison between PPOS and GnRHa-long protocol in clinical outcome with the first IVF/ICSI cycle: a randomized clinical trial
Keane et al. Higher β-HCG concentrations and higher birthweights ensue from single vitrified embryo transfers
Huang et al. Timing of frozen-thawed embryo transfer after controlled ovarian stimulation in a non-elective freeze-all policy
Benmachiche et al. Impact of mid-luteal phase GnRH agonist administration on reproductive outcomes in GnRH agonist-triggered cycles: a randomized controlled trial
Seow et al. Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial
Song et al. Administration effects of single‑dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta‑analysis of randomized controlled trials
Pelinck et al. Perinatal outcome in singletons after modified natural cycle IVF and standard IVF with ovarian stimulation
Huang et al. Decreased endometrial thickness is associated with higher risk of neonatal complications in women with polycystic ovary syndrome
Su et al. Age is a major prognosticator in extremely low oocyte retrieval cycles
Qiu et al. The influence of polycystic ovarian syndrome on obstetric and neonatal outcomes after frozen-thawed embryo transfer
Pelinck et al. Is the birthweight of singletons born after IVF reduced by ovarian stimulation or by IVF laboratory procedures?
Coskun et al. The role of anti-Mullerian hormone in predicting the response to clomiphene citrate in unexplained infertility
Luo et al. The role of serum vitamin D in patients with normal ovarian reserve undergoing the first IVF/ICSI cycle
Jin et al. Live birth rates after natural cycle versus hormone replacement therapy for single euploid blastocyst transfers: a retrospective cohort study
Bortoletto et al. Time from oocyte retrieval to frozen embryo transfer in the natural cycle does not impact reproductive or neonatal outcomes
Yılmaz et al. Effect of the afterloaded external guidance embryo transfer technique on pregnancy rates in single embryo transfer cycles
Lin et al. Progestin-primed ovarian stimulation with clomiphene citrate supplementation may be more feasible for young women with diminished ovarian reserve compared with standard progestin-primed ovarian stimulation: A retrospective study
Chen et al. Evaluative effectiveness of follicular output rate, ovarian sensitivity index, and ovarian response prediction index for the ovarian reserve and response of low-prognosis patients according to the POSEIDON criteria: a retrospective study